China's drug regulator approved Humanwell Healthcare (SHA:600079) subsidiary Wuhan Humanwell Pharmaceutical's drug registration for its hydrocortisone sodium succinate injection.
The injection is indicated for patients with toxic infections, anaphylactic shock, severe adrenocortical conditions, severe bronchial asthma and prevention of acute graft rejection, according to a Tuesday filing with the Shanghai bourse.